WP
PLX icon

WealthPLAN Partners’s Protalix BioTherapeutics PLX Stock Holding History

WealthPLAN Partners’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-575
Closed -$1.15K – 913
2023
Q2 		$1.15K Buy
+575
New +$1.37K ﹤0.01% 1131

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

WealthPLAN Partners's PLX Position: Q3 2023 in Review

WealthPLAN Partners sold out of Protalix BioTherapeutics (PLX) in Q3 2023, closing a stake of 575 shares — an estimated $1.15K sold.

WealthPLAN Partners first reported a position in PLX in Q2 2023 and held it in 1 quarter. The position peaked at $1.15K in Q2 2023. 61 funds tracked by Wall St. Rank hold PLX as of Q3 2023.

  • WealthPLAN Partners reported no remaining Protalix BioTherapeutics position as of Q3 2023 after selling out during the quarter.
  • WealthPLAN Partners sold 575 Protalix BioTherapeutics shares in Q3 2023, an estimated $1.15K.
  • WealthPLAN Partners first reported a position in Protalix BioTherapeutics in Q2 2023 and held it in 1 quarter.
  • WealthPLAN Partners's Protalix BioTherapeutics position peaked at $1.15K in Q2 2023.
  • 61 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2023.

Based on WealthPLAN Partners's 13F filing for Q3 2023, filed 2 Nov 2023.